In order to generally mitigate the risk for potential on-target/off-tumor toxicity associated with targeting CSPG4, our group has developed the generation of CSPG4-specific CAR-T cells via mRNA-electroporation [17]. This evidence concerns the gene CSPG4 and neoplasm.